Wall Street brokerages expect Supernus Pharmaceuticals Inc (NASDAQ:SUPN) to announce earnings of $0.31 per share for the current quarter, according to Zacks Investment Research. Six analysts have made estimates for Supernus Pharmaceuticals’ earnings. The lowest EPS estimate is $0.21 and the highest is $0.44. Supernus Pharmaceuticals reported earnings per share of $0.44 during the same quarter last year, which would indicate a negative year-over-year growth rate of 29.5%. The company is expected to issue its next earnings results on Tuesday, February 26th.

According to Zacks, analysts expect that Supernus Pharmaceuticals will report full-year earnings of $1.87 per share for the current year, with EPS estimates ranging from $1.78 to $2.02. For the next financial year, analysts forecast that the firm will report earnings of $2.44 per share, with EPS estimates ranging from $2.10 to $2.89. Zacks’ EPS averages are a mean average based on a survey of analysts that follow Supernus Pharmaceuticals.

Supernus Pharmaceuticals (NASDAQ:SUPN) last issued its earnings results on Tuesday, November 6th. The specialty pharmaceutical company reported $0.52 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.43 by $0.09. Supernus Pharmaceuticals had a net margin of 25.89% and a return on equity of 30.30%. The company had revenue of $102.99 million for the quarter, compared to analysts’ expectations of $100.75 million. During the same quarter last year, the company posted $0.29 earnings per share. The firm’s quarterly revenue was up 28.1% on a year-over-year basis.

Several research analysts have recently weighed in on the stock. Piper Jaffray Companies reiterated a “hold” rating and set a $44.00 price target on shares of Supernus Pharmaceuticals in a research note on Thursday, August 9th. Cantor Fitzgerald set a $57.00 price target on shares of Supernus Pharmaceuticals and gave the stock a “buy” rating in a research note on Wednesday, November 7th. Zacks Investment Research cut shares of Supernus Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, August 1st. Mizuho assumed coverage on shares of Supernus Pharmaceuticals in a research note on Monday, September 17th. They set a “buy” rating and a $61.00 price target on the stock. Finally, B. Riley dropped their price target on shares of Supernus Pharmaceuticals from $68.00 to $65.00 and set a “buy” rating on the stock in a research note on Monday. Four analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $56.00.

Shares of SUPN stock opened at $45.11 on Wednesday. Supernus Pharmaceuticals has a 12-month low of $34.90 and a 12-month high of $61.25. The company has a debt-to-equity ratio of 0.77, a quick ratio of 2.65 and a current ratio of 2.82. The company has a market capitalization of $2.36 billion, a P/E ratio of 35.80 and a beta of 0.92.

Several hedge funds have recently made changes to their positions in the company. BlackRock Inc. raised its position in shares of Supernus Pharmaceuticals by 4.1% during the 3rd quarter. BlackRock Inc. now owns 8,003,001 shares of the specialty pharmaceutical company’s stock valued at $402,951,000 after purchasing an additional 312,332 shares during the period. FMR LLC raised its position in shares of Supernus Pharmaceuticals by 151.9% during the 3rd quarter. FMR LLC now owns 2,371,321 shares of the specialty pharmaceutical company’s stock valued at $119,396,000 after purchasing an additional 1,430,021 shares during the period. Wells Fargo & Company MN raised its position in shares of Supernus Pharmaceuticals by 6.8% during the 2nd quarter. Wells Fargo & Company MN now owns 957,210 shares of the specialty pharmaceutical company’s stock valued at $57,290,000 after purchasing an additional 61,100 shares during the period. Renaissance Technologies LLC raised its position in shares of Supernus Pharmaceuticals by 191.3% during the 2nd quarter. Renaissance Technologies LLC now owns 884,690 shares of the specialty pharmaceutical company’s stock valued at $52,949,000 after purchasing an additional 580,990 shares during the period. Finally, Janus Henderson Group PLC raised its position in shares of Supernus Pharmaceuticals by 21.6% during the 2nd quarter. Janus Henderson Group PLC now owns 665,392 shares of the specialty pharmaceutical company’s stock valued at $39,824,000 after purchasing an additional 118,289 shares during the period. Hedge funds and other institutional investors own 98.30% of the company’s stock.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy.

Featured Article: How to Use the New Google Finance Tool

Get a free copy of the Zacks research report on Supernus Pharmaceuticals (SUPN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.